Meropenem Qilu

Meropenem, the active ingredient in Meropenem Qilu, is a carbapenem presented as an injection for intravenous use. It treats serious bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, nosocomial pneumonia, meningitis and septicemia in hospitalized patients.

GNH USA supplies Meropenem Qilu as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals worldwide.

Meropenem is a broad‑spectrum carbapenem antibiotic indicated for severe bacterial infections in the hospital setting.

Complicated intra‑abdominal infections: provides effective bacterial eradication in patients with intra‑abdominal sepsis. Complicated urinary tract infections: clears resistant uropathogens causing complicated UTIs. Nosocomial pneumonia: treats hospital‑acquired lung infections, including ventilator‑associated pneumonia. Meningitis: penetrates the cerebrospinal fluid to eradicate causative bacteria. Septicemia: rapidly reduces bacterial load in bloodstream infections.

Common Side Effects: - Nausea or vomiting - Diarrhea, including mild Clostridioides difficile colitis - Rash or mild skin erythema - Headache - Infusion site pain or phlebitis - Transient elevation of liver enzymes

Serious or Rare Side Effects: - Seizures, especially in patients with renal impairment or CNS disorders - Severe allergic reactions such as anaphylaxis - Clostridioides difficile‑associated colitis requiring medical intervention - Neutropenia or other significant hematologic abnormalities - Thrombocytopenia - Acute renal impairment or worsening of existing kidney dysfunction

Before initiating therapy, consider patient‑specific factors and monitor for adverse events. - Renal function: adjust dosing in patients with impaired clearance. - Allergy: verify no history of hypersensitivity to carbapenems or other β‑lactams. - Seizure risk: monitor closely in patients with pre‑existing CNS disorders. - Pregnancy: use only when the potential benefit justifies the potential risk to the fetus. - Drug interactions: review concomitant medications that may lower seizure threshold or affect renal function. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Meropenem may interact with several co‑administered drugs, requiring clinical vigilance.

Major Interactions (Avoid): - Valproic acid: meropenem can markedly reduce serum valproate concentrations, increasing seizure risk. - CNS‑active agents (e.g., quinolones, aminoglycosides): combined use may heighten neurotoxicity, including seizures.

Moderate Interactions (Monitor Closely): - Loop diuretics: may potentiate nephrotoxic effects, necessitating renal function monitoring. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): concurrent use can affect renal perfusion. - Probenecid: may decrease renal clearance of meropenem, leading to higher plasma levels. - Other β‑lactam antibiotics: concurrent use may increase risk of additive toxicity without added benefit.